Albertin G, Malendowicz L K, Tortorella C, Mazzocchi G, Nussdorfer G G
Department of Human Anatomy and Physiology (Section of Anatomy), University of Padua, I-35121, Padua, Italy.
Peptides. 2000 Mar;21(3):413-7. doi: 10.1016/s0196-9781(00)00162-5.
Adrenomedullin (ADM) has been recently found to directly inhibit agonist-stimulated aldosterone secretion by dispersed zona glomerulosa (ZG) cells and to stimulate basal catecholamine release by adrenomedullary fragments. In light of the fact that catecholamines enhance aldosterone secretion acting in a paracrine manner, we have investigated whether these two effects of ADM may interact when the integrity of the adrenal gland is preserved. ADM increased basal aldosterone output by adrenal slices containing a core of adrenal medulla, and the effect was blocked by the beta-adrenoceptor antagonist l-alprenolol. In contrast, ADM evoked a moderate inhibition of K(+)-stimulated aldosterone production, and the blockade was complete in the presence of l-alprenolol. The in vivo bolus injection of ADM did not affect plasma aldosterone concentration (PAC) in rats under basal conditions. Conversely, when rat ZG secretory function was enhanced (by sodium restriction or infusion with angiotensin-II [ANG-II]) or depressed (by sodium loading or infusion with the angiotensin-converting enzyme inhibitor captopril), ADM evoked a sizeable decrease or increase in PAC, respectively. The prolonged infusion with the ADM receptor antagonist ADM(22-52) caused a further enhancement of PAC in sodium-restricted or ANG-II-treated rats, and a further moderate decrease of it in sodium-loaded or captopril-administered animals. RIA showed that ADM plasma concentration did not exceed a concentration of 10(-11) M in any group of animals. Under basal conditions, ADM adrenal content was 1.2-2.0 pmol/g, which may give rise to local concentrations higher than 10(-8) M (i.e. well above the minimal effective ones in vitro). ADM adrenal concentration was markedly increased (from two-fold to three-fold) by both ZG stimulatory and suppressive treatments. Collectively, our findings suggest that in vivo 1) ADM, in addition to directly inhibit aldosterone secretion, may enhance it indirectly by eliciting catecholamine release, the two actions annulling each other under basal conditions; 2) under conditions leading to enhanced aldosterone secretion, the direct inhibitory effect of ADM prevails over the indirect stimulatory one, and the reverse occurs when aldosterone secretion is decreased; and 3) the modulatory action of ADM on the aldosterone secretion has a physiological relevance, endogenous ADM being locally synthesized in adrenals.
最近发现,肾上腺髓质素(ADM)可直接抑制分散的球状带(ZG)细胞受激动剂刺激后的醛固酮分泌,并刺激肾上腺髓质碎片释放基础儿茶酚胺。鉴于儿茶酚胺以旁分泌方式增强醛固酮分泌,我们研究了在肾上腺完整性得以保留的情况下,ADM的这两种作用是否会相互影响。ADM可增加含有肾上腺髓质核心的肾上腺切片的基础醛固酮分泌量,且该作用可被β-肾上腺素能受体拮抗剂l-阿普洛尔阻断。相反,ADM可适度抑制钾离子刺激的醛固酮生成,且在l-阿普洛尔存在的情况下,这种阻断作用是完全的。在基础条件下,对大鼠进行ADM体内大剂量注射并不影响血浆醛固酮浓度(PAC)。相反,当大鼠ZG分泌功能增强(通过限钠或输注血管紧张素-II [ANG-II])或受到抑制(通过钠负荷或输注血管紧张素转换酶抑制剂卡托普利)时,ADM分别引起PAC显著降低或升高。用ADM受体拮抗剂ADM(22 - 52)进行长时间输注,在限钠或ANG-II处理的大鼠中导致PAC进一步升高,而在钠负荷或卡托普利给药的动物中导致PAC进一步适度降低。放射免疫分析显示,在任何一组动物中,ADM血浆浓度均未超过10(-11) M。在基础条件下,ADM肾上腺含量为1.2 - 2.0 pmol/g,这可能导致局部浓度高于10(-8) M(即远高于体外最小有效浓度)。通过ZG刺激和抑制处理,ADM肾上腺浓度均显著增加(从两倍到三倍)。总体而言,我们的研究结果表明,在体内:1)ADM除了直接抑制醛固酮分泌外,还可能通过引发儿茶酚胺释放间接增强醛固酮分泌,这两种作用在基础条件下相互抵消;2)在导致醛固酮分泌增强的条件下,ADM的直接抑制作用超过间接刺激作用,而当醛固酮分泌减少时则相反;3)ADM对醛固酮分泌的调节作用具有生理相关性,内源性ADM在肾上腺中局部合成。